Tier 2 — strong

Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study

Y Nakamura, H Watanabe, A Tanaka, J Nishihira, N Murayama
European review for medical and pharmacological sciences 2022 26(23):8700-8712

Bibliography

PubMed
PMID 36524489
DOI
10.26355/eurrev_202212_30541
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample80 adults aged 60–75 without cognitive impairment
InterventionDaily beverage containing quercetin glycoside equivalent to isoquercitrin 110 mg
Duration40 weeks
EndpointsCognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2022, this source examined brain, cognition and sleep. Design: Randomized double-blind placebo-controlled trial. Sample/model: 80 adults aged 60–75 without cognitive impairment. The exposure or intervention was Daily beverage containing quercetin glycoside equivalent to isoquercitrin 110 mg. Follow-up or treatment period: 40 weeks.

Reaction time improved on the cognitive battery. Cerebral blood-flow measures did not differ significantly between groups.

Healthy older-adult beverage trial. Amyloid reduction and dementia prevention were not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Reaction time improved on the cognitive battery.
  • Cerebral blood-flow measures did not differ significantly between groups.
  • The recorded outcome domains were Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Daily beverage containing quercetin glycoside equivalent to isoquercitrin 110 mg; 40 weeks.

What this study can and cannot tell us

  • Healthy older-adult beverage trial. Amyloid reduction and dementia prevention were not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Assessment of the Efficacy of Quercetin in Adult Patients With Autism Spectrum Disorder: A Randomized, Triple-Blind, Placebo-Controlled Trial
Anahid Rezaeifar et al. · Human psychopharmacology · 2026
Tier 2
Two-month period of 500 mg lecithin-based delivery form of quercetin daily dietary supplementation counterbalances chronic fatigue symptoms: A double-blind placebo controlled clinical trial
Mariangela Rondanelli et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
Tier 2
Memory-Enhancing Effect of 8-Week Consumption of the Quercetin-Enriched Culinary Herbs-Derived Functional Ingredients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Jintanaporn Wattanathorn et al. · Foods (Basel, Switzerland) · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology